May 15, 2020 · MUC1-AuNCs exhibited red fluorescence emission with excellent stability over a wide pH range and under strong illumination. Confocal images showed that the synthesized MUC1-AuNCs efficiently targeted mucin overexpressing 4T1 cancer cells, but were not observed in 293T normal cells.

In this study, we constructed nanoparticles (NPs) to deliver an mRNA vaccine encoding tumor antigen MUC1 to dendritic cells (DCs) in lymph nodes to activate and expand tumor-specific T cells. An anti-CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) monoclonal antibody was combined with the mRNA vaccine to enhance the anti-tumor benefits.

Apr 25, 2012 · The association between the appearance of T antigen and the overexpression of MUC1 was further confirmed by transfecting MDA-MB-231 cells and murine 4T1 mammary carcinoma cells with cDNA for MUC1 and using an RNAi approach to inhibit the expression of MUC1 gene in T47D cells.

Jun 19, 2020 · The present study developed a novel Toll‑like receptor 7 (TLR7) agonist‑conjugated MUC1 peptide vaccine (T7‑MUC1), which elicited an effective immune response and a robust antitumor effect in a mouse breast cancer model.

Dec 1, 2022 · Our group developed a novel TLR7 agonist-conjugated MUC1 peptide vaccine that elicited effective immune responses and robust antitumor effects in a mouse breast cancer model [14]. However, appropriate immune stimulators still need to be studied due to the weak immunogenicity of MUC1 peptides.

Moreover, T7-MUC1 remarkably promoted cytokine production in vitro within mouse splenic lymphocytes and bone marrow-derived DCs, while inducing a DC-cytokine-mediated anticancer killer response in MUC1-overexpressing cells. Further, T7-MUC1 conjugate-immunized mice decreased 4T1 tumor weights by ≥70% relative to the control.

Our group previously demonstrated that calreticulin (CRT) translocated type I transmembrane glycoprotein mucin 1 (MUC1), a breast cancer antigen, to the surface of 4T1 cells, and that treatment with MUC1-CRT-primed 4T1 cell-treated DCs induced apoptosis in a …

Sep 1, 2024 · The level of secretion of ATP was significantly increased in 4T1 cells after MUC1@ACS NPs treatment. As released DAMPs during necroptotic ICD can induce maturation of DCs [50, 51], we then investigated the effect of supernatants of tumor cells on the maturation of freshly isolated BMDCs (Fig. 5 D).

The present study developed a novel Toll-like receptor 7 (TLR7) agonist-conjugated MUC1 peptide vaccine (T7-MUC1), which elicited an effective immune response and a robust antitumor effect in a mouse breast cancer model.

Combined therapy with MUC1 mRNA nanovaccine and anti-CTLA-4 mAb could reduce immunosuppressive TME, increase the infiltration of CD8 + T cells into tumor sites, and enhance anti-tumor cytotoxic T-lymphocyte activity when compared with each monotherapy.